145 results about "Lung alveolus" patented technology

Method for providing ventilatory settings with regard to the airway pressure levels of an artificial ventilator, the artificial ventilator is connected to a lung, including the steps of obtaining data samples of a gas concentration of the expired gas over a single breath; selecting a plurality of data samples from the obtained data samples; calculating a tracing value being sensitive to changes of alveolar dead space on the basis of the selected data samples; repeating steps a), b) and c) for obtaining a plurality of tracing values; and changing at least one airway pressure level of the artificial ventilator, wherein from an observation of a resulting course of the plurality of calculated tracing values an airway pressure level at which alveolar opening or lung overdistension or lung open condition or alveolar closing occurs is detected. Apparatus for providing ventilatory settings with regard to the airway pressure levels of an artificial ventilator is also disclosed.

The invention relates to a treatment quality management method of a breathing machine. The method comprises: step one, monitoring flowing speed and waveform information of a pipe of a breathing machine; step two, monitoring pressure and waveform information in the pipe of the breathing machine; step three, monitoring oxygen concentration information in an oxygen channel and/or breathing machine pipe; step four, monitoring oxygen flow information in the oxygen channel and sending the information to a cloud and a monitoring terminal; step five, monitoring blood oxygen saturation and pulse rate information in blood of a breathing machine user and sending the information to the cloud and the monitoring terminal; step six, monitoring CO2 pressure dividing information in alveolar of the breathing machine user or a CO2 waveform of an exhalation end in a breathing machine pipe line and sending the monitored information to the cloud and the monitoring terminal; and step seven, monitoring comparison of the terminal and a preset threshold value and determining whether treatment of the breathing machine is normal. With the method, the overall progress is improved based on real-time monitoring of feedback of equipment data and patient data.

The invention discloses novel coronavirus 2019-nCoV fluorescent RPA detection primers, a probe, a kit and a method. The kit comprises novel coronavirus 2019-nCoV specific primers shown in SEQ ID NO. 1-2 and a probe shown in SEQ ID NO. 3. According to the invention, the existence of the novel coronavirus 2019-nCoV ORF1ab gene and the internal reference gene RNase P is simultaneously detected by adopting a single-tube double-fluorescence channel, and the existence of the novel coronavirus 2019-nCoV RNA in pulmonary alveolar lavage fluid, nasal swab, pharyngeal swab, sputum and other samples canbe detected. The method is short in detection time and suitable for clinical and bedside virus nucleic acid rapid screening, the kit has extremely high sensitivity and specificity, an internal reference gene is added into the detection system, and quality monitoring is performed on the extraction and amplification process of the sample according to the detection result of the internal reference gene.

The invention belongs to the fields of cell biology and tumor tissue engineering materials and provides a three-dimensional tumor model decellularization porous scaffold, a construction method and application thereof. The whole pig lung scaffold is prefrozen, a uniform part without obvious bronchi is selected and sliced, purified water and PBS are added for cleaning until no blood streak is formed, removing cells with sodium dodecyl sulfate and TritonX-100, and freezing, drying and chemical crosslinking methods are adopted, so that a crosslinked decellularization pig lung three-dimensional tumor model scaffold is obtained. The three-dimensional tumor model decellularization porous scaffold provided by the invention has the advantages that decellularization matrix sourced from pig lung tissues is taken as a scaffold material for constructing a tumor model, on the basis of effectively removing cell components, a pulmonary alveolus-bronchus structural vein network is reserved as soon as possible, a natural extracellular matrix microenvironment can be simulated, and cell adhesion, growth and proliferation are facilitated. The in vitro constructed three-dimensional tumor model after cells are inoculated has a tissue structure closer to an in vivo tissue and is applicable to screening study of anticancer drugs.

The invention discloses a method for preparing a pneumonia rat model and a model evaluation method, and belongs to the technical field of biology. The method for establishing the pneumonia rat model is non-invasive and safe to rats, does not damage other organs of rats in the whole process, and effectively avoids the death of the rats. Besides, the method has simple operation and high success rate. According to the pneumonia rat model established by the method, pseudomonas aeruginosa in bronchoalveolar lavage fluid is obviously increased, inflammatory factors IL-4 and TNF-alpha are obviously increased, the level of adhesion factor IFN-gamma is obviously reduced, and the number of leukocytes is obviously increased. Meanwhile, the lung index is also obviously increased, which indicates thatthe model is established well.

A method for generating progeny of an African swine fever (ASF) virus includes providing an isolated or purified fetal porcine lung alveolar macrophage cell capable of replicating the ASF virus, wherein the cell is cultured for at least 5 passages; exposing the cell to the ASF virus; and allowing the ASF virus to replicate in the cell; thereby generating progeny of the ASF virus.

This invention provides pertains to the discovery that that nicotine interrupts molecular signaling between endodermal and mesodermal cells of the lung alveolus. Treatment of the lung with specific molecular agents (e.g., PPAR gamma agonists) can prevent and/or reverse the injury caused by nicotine.

The invention provides a culture medium and method for inducing human pluripotent stem cells to be differentiated into alveolar cells or alveolar organs, and particularly relates to a culture medium and method for inducing the human pluripotent stem cells to be differentiated into lung precursor cells or alveolar cells by using a small molecule activator/inhibitor. The cells obtained by induced differentiation express typical lung precursor cells and alveolar cell biomarkers, and a three-dimensional human alveolar organ has an alveolar-like blister structure and can be used as a material for toxicological research, drug screening and lung disease research.

The invention discloses a reversion pulmonary fibrosis nano preparation and a preparation method thereof, and relates to a synthetic E5 and polypeptide Z modified nano preparation and a carrier thereof. The nano preparation is capable of, through E5 targeted circulation fibrocyte CXCR4, CCR2 and CCR7 acceptors, reaching a pulmonary fibrosis injured part in a fixed point, and avoiding from being packaged and cleared by in-vivo macrophages and proteins; and through polypeptide Z, specific-targeting alveolar epithelial cells II of a high-expression integrin acceptor AlphavBeta6, and efficiently targeting and delivering the nano preparation. The nano preparation contains an anti-oxidant and/or a fibroblast activation inhibitor. A purpose of reversing pulmonary fibrosis is achieved by controlling an alveolar epithelial cell II oxidative stress level and inhibiting fibroblast activation double-channel control.

The invention discloses a method for pathologically fixing an experimental animal lung, which comprises the following steps of: (1) filling a fixing liquid, namely, suspending a filling container filled with the fixing liquid onto an isolated animal lung, inserting the liquid outlet end of a filling tube connected with the filling container into trachea of the isolated animal lung, and filling the fixing liquid into pulmonary alveoli of the animal lung by utilizing the hydrostatic pressure formed by the height difference between the liquid surface of the fixing liquid and the horizontal surface of the animal lung so as to naturally extend the animal lung; and (2) soaking the fixing liquid, namely, completely soaking the animal lung obtained in the step (1) into the fixing liquid to be fixed. The method is convenient to operate, low in cost and fast in fixing; the method can be controlled in a normalizing manner; and the method can enable the animal lung to be completely, uniformly and naturally filled, so that natural shapes of lung tissues is favorably stored and the need of observing pathological change of small blood vessels and small tracheas of the lung is met.

A bi-lateral endobronchial suctioning device includes actuating and articulating components that allow a provider to accurately suction both right and left bronchi as well as the trachea in a controlled and safe manner. A control mechanism is used to manipulate the actuating components in tubes forming a suction catheter to flex the tip of the bi-lateral endobronchial suctioning device to the left and to the right when the device is inserted through an endotracheal tube or other similar device, to enable directional control of a catheter for suctioning the lungs or trachea. The device further includes a bronchoalveolar lavage (BAL) port allowing sterile saline or other liquids or fluids to travel down the catheter lumen to assist with breaking up thick secretions which collect in the airways.

The invention discloses an application of iodine in preparation of a medicine for preventing and treating respiratory tract infectious diseases and a method for preparing iodine-containing aerosol with low particle size. According to the invention, iodine is dissolved in pure water and an oily solvent to respectively prepare two iodine solution atomizing agents, and the two iodine solution atomizing agents are atomized into iodine-containing aerosol by an atomizer to be inhaled into the respiratory tract, so that pathogens are quickly and efficiently killed, and the iodine-containing aerosol becomes the only specific medicine for treating respiratory virus infection lacking effective treatment medicines; and more effective and convenient treatment medicines are provided for infection of respiratory bacteria, mycoplasmas, fungi and the like. The method is mainly characterized in that iodine is prepared into a low-concentration iodine solution and atomized into iodine-containing aerosol, so that the density of iodine is greatly reduced, the irritation is greatly reduced, and iodine molecules enter the respiratory tract to kill pathogens; the iodine-containing aerosol with low particle size can reach pulmonary alveoli to directly screen and kill viruses in the pulmonary alveoli, so that critical and severe pulmonary infection patients can be quickly out of danger, and mild diseases can be quickly cured.

The invention relates to a lung tissue single-channel fixing instrument and overcomes the defects that existing lung tissue fixing is low in speed, fixing liquid immersion efficiency is affected, the exposure time of lung tissues is excessively long, and the experiment result is affected. The lung tissue single-channel fixing instrument comprises a fixing body, the fixing body is internally provided with a containing cavity for containing fixing liquid, the fixing body is provided with an opening communicated with the containing cavity, a sealing cover is arranged at the opening, the side wall of the fixing body is provided with a side channel communicated with the containing cavity, and the side channel is internally provided with an air pulling core. As the air pulling core moves outwards, the volume of the containing cavity is increased, so that the pressure intensity in the containing cavity is lowered, a negative pressure state is formed, in the negative pressure environment, air in the lung tissues is discharged rapidly, under the elasticity of the lung tissues, the fixing liquid is immersed into pulmonary alveoli rapidly, and the pulmonary alveoli recovers to the original shape, so that lung tissue cells are integrally fixed, and subsequent immunohistochemistry and pathological analysis are facilitated.

The invention relates to the technical field of medicine, in particular to a lung knock injury animal model construction method which can truly reflect physical parameters related to explosion and a complex action process generated by interaction of the physical parameters and can achieve quantitative evaluation on the range, grade and severity of lung injury. A lung knock injury animal model constructed by the method verifies that the resveratrol has a relatively good curative effect in treating lung knock injury, has the advantages of wide source, safety, difficulty in generating drug resistance and the like, and can reduce lung tissue bleeding, alveolar septum rupture and inflammatory cell infiltration of a lung knock injury rat and relieve the lung tissue edema.

The invention relates to a model for simulating and demonstrating the pathogenesis of pulmonary edema caused by mitral valve stenosis, belonging to a medical teaching facility, in particular to a teaching tool for demonstrating the pathogenesis of pulmonary edema caused by mitral valve stenosis. The teaching tool mainly comprises a conical pulmonary artery model, a branched pulmonary artery model, an alveolar wall capillary model, an alveolar model, a pulmonary vein model, a heart model, a mitral valve model and a mitral valve cusp adjustment switch which form a model system for simulating and demonstrating the pathogenesis of pulmonary edema caused by mitral valve stenosis. The device has a simple structure, is convenient to operate, can be used to teach intuitively and pellucidly and is beneficial to culturing the problem observing and analyzing capacity of the students.

The present disclosure provides the use of mesenchymal stem cells (MSC) in the treatment of viral infection and/or complications caused by the viral infection. MSC can highly express multiple antioxidative stress genes and secrete multiple antioxidative stress factors under the stimulation of oxidative stress, inhibit inflammatory reaction and excessive activation of immune cells, thus improving inflammatory indexes and myocardial injury indexes of human bodies. MSC can regulate the expression profile of monocyte genes and monocyte toxicity genes in patients with viral infection, inhibit the excessive immune response, protect alveolar function, and reduce the damage of lung and whole body organs in patients with viral infection. MSC can regulate the expression of antivirus-related genes and coagulation-related genes of terminally differentiated cell subsets in patients with viral infection, inhibit the excessive activation of monocytes in patients with viral infection, and effectively treat the complications of patients with viral infection.

ACE receptors are affected in severe acute respiratory distress syndrome related coronaviruses. ACE genes are directly related to the morbidity and mortality of those with cystic fibrosis. The thick, sticky mucus in the respiratory, and digestive systems, is seen in the inherited disease cystic fibrosis. Viral induced sticky mucus in the respiratory and digestive systems can also be appreciated as a response to viral pathogens where the cycle of mucus production in vivo induces the recruitment of more mucus production to the extent that cellular damage occurs within the lower respiratory track requiring intubation as a life saving measure. In the most severe cases mechanical intubation fails due to the fact that no control over the recruitment of mucus production was achieved at the onset. SARS pathology shows inflammatory exudation in the alveoli and interstitial tissue, with hyperplasia of fibrous tissue and fibrosis. Inherited cystic fibrosis pathology shows atelectasis, mucoid impaction, acute and chronic inflammation, bronchiectasis, cyst formation, and fibrosis widespread. A virally induced disorder in relations to ACE2 receptors can be treated successfully at the early onset with inherited cystic fibrosis disease mimicking techniques with the efforts of minimizing the activity and utilization of the ACE2 receptor. Cystic fibrosis lung infections, and opportunistic pathogens contribute to chronic airway inflammation that is characterized by neutrophil/macrophage infiltration, cytokine release and ceramide accumulation. In terms of virally induced forms off ACE2 receptor pathologies, as it related to coronavirus such as Covid 19, presumably ceramide precursors which aid in intracellular transport of the virus into the cell via inflammation and remodeling is present in alveolar tissues of the lung in patients with cystic fibrosis while the same pathology occurs in patients with virally induced forms of ACE2 pathology which to often progresses to SARS or ARDS.